作者
Yvonne Naegelin, Peter Naegelin, Stefanie von Felten, Johannes Lorscheider, Judith Sonder, Bernard MJ Uitdehaag, Barbara Scotti, Chiara Zecca, Claudio Gobbi, Ludwig Kappos, Tobias Derfuss
发表日期
2019/3/1
期刊
JAMA neurology
卷号
76
期号
3
页码范围
274-281
出版商
American Medical Association
简介
Importance
Therapeutic options for patients with secondary progressive multiple sclerosis (SPMS) are limited.
Objective
To analyze disability progression in patients with SPMS treated with rituximab compared with matched control patients never treated with rituximab.
Design, Setting, and Participants
This retrospective cohort study analyzed data obtained from patients with SPMS at 3 multiple sclerosis centers located in Basel and Lugano, Switzerland, and Amsterdam, the Netherlands, from 2004 to 2017. Patients were included for analysis if they had received a diagnosis of SPMS, were treated (57 eligible; 54 included) or never treated (504 eligible; 59 included) with rituximab, and had at least 1 follow-up visit. The variables used for propensity score matching were sex, age, Expanded Disability Status Scale (EDSS) score, and disease duration. Follow-up duration was up to 10 years, with a mean (SD) of 3.5 (2.6 …
学术搜索中的文章
Y Naegelin, P Naegelin, S von Felten, J Lorscheider… - JAMA neurology, 2019